LOUISVILLE, Kentucky, Aug. 12, 2026, 11:48 EDT
- July’s CPI-W indicates a tentative Social Security COLA for 2027 of about 3.1%.
- Medical-care services increased by 0.6% in July, as the CPI-W showed no change.
- Shares of Humana increased 2.6% to $382.52 as of 11:14 a.m. EDT.
Shares of Humana Inc. NYSE:HUM gained on Wednesday, coinciding with heightened interest in the 2027 Social Security cost-of-living adjustment. The latest CPI-W figure for July suggests an initial increase of around 3.1%. Still, the principal challenge for the Medicare insurer lies in healthcare expenses rather than payments to retirees.
The estimate remains preliminary. Social Security calculates using the average CPI-W from July through September, comparing it to the same period in the previous year. Figures for August and September may still affect the final outcome.
| CPI-W input | Index level | Role in 2027 COLA |
|---|---|---|
| July 2025 | 316.349 | Used as prior-year base |
| August 2025 | 317.306 | Used as prior-year base |
| September 2025 | 318.139 | Used as prior-year base |
| Q3 2025 average | 317.265 | Reference base for comparison |
| July 2026 | 327.104 | 3.1% higher than the base |
An additional 3.1% rise would mean roughly $64 more each month for the projected 2026 average retired-worker benefit of $2,071. This figure is for illustration and does not represent an official 2027 benefit estimate. The average may fluctuate as new retirees start collecting benefits or if there are changes to existing payments.
The inflation picture presents more challenges for Humana. In July, the unadjusted CPI-W remained unchanged. Seasonally adjusted, medical care increased by 0.4%, and medical-care services advanced by 0.6%. Prescription-drug prices declined by 0.8%.
| July inflation measure | Monthly change | Humana investor read-through |
|---|---|---|
| CPI-W, unadjusted | 0.0% | COLA calculation unchanged |
| Medical care | +0.4% | Overall healthcare expenses increased |
| Medical-care services | +0.6% | Pressure on provider costs intensified |
| Prescription drugs | -0.8% | Monthly decline partially balanced trends |
Humana’s Medicare Advantage premiums are not determined by Social Security benefits. Instead, these rates are based on federal payments, member risk, and medical usage. While the COLA can help household finances, it does not have a direct impact on the insurer’s profit margin.
The margin remains narrow. Humana posted a 91.2% Insurance benefit ratio for the second quarter. This resulted in 8.8 cents remaining from each premium dollar before factoring in operating expenses and other components. The midpoint for the full year, at 92.75%, leaves 7.25 cents.
| Humana measure | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $40.87 billion | $32.39 billion | Up 26.2% |
| Adjusted pretax income | $1.25 billion | $1.02 billion | Rising 22.7% |
| Adjusted EPS | $7.61 | $6.27 | Increasing 21.4% |
| Adjusted Insurance operating income | $824 million | $770 million | Ahead 7.0% |
| Insurance benefit ratio | 91.2% | 89.9% | Higher by 1.3 points |
Revenue and adjusted earnings increased at a quicker pace than operating income for Insurance. The higher benefit ratio accounts for some of the difference. This also highlights how even one month of medical inflation can have a bigger impact than the main COLA figure.
Chief Executive Jim Rechtin stated that results from the first half were “right where we said we’d be.” He attributed improved earnings to enhanced clinical care and increased efficiency. The company maintained its adjusted 2026 earnings per share forecast of at least $9.00. Humana earnings release
Humana anticipates around 25% expansion in individual Medicare Advantage membership this year, increasing scale but also heightening the financial impact of any errors in pricing or utilization.
Analysts have become more optimistic, but potential gains remain modest. MarketBeat’s compilation from 30 analysts indicates a Moderate Buy rating, with an average price target of $395.22. This figure stands just 3.3% above the price quoted on Wednesday.
| Analyst or consensus | Recommendation | Price target | Date |
|---|---|---|---|
| 30-analyst consensus | Moderate Buy: 15 positive ratings, 14 holds, 1 sell | $395.22 average | Aug. 12 snapshot |
| JPMorgan | Neutral | $393, increased from $316 | Aug. 10 |
| Morgan Stanley | Equal Weight, upgraded from Underweight | $370, up from $249 | Aug. 4 |
| Barclays | Equal Weight | $407, raised from $344 | July 31 |
| Piper Sandler | Overweight, promoted from Hold | $463 | July 30 |
| Guggenheim | Buy | $471, increased from $269 | July 30 |
Risks: Actual medical usage could surpass pricing projections. Reduced Medicare Star Ratings are already impacting 2026 profit forecasts. The ultimate COLA outcome could also significantly deviate from the initial indication given in July.
The 2027 COLA trend provides helpful context for Humana investors, though it is not the primary factor driving earnings. Key influences are benefit costs, federal payments, and the company’s ability to achieve a 25% increase in membership.
Related articles: NYSE:HUM
